If you are considering long-term use, the dose escalation phase is not separate from the safety equation
Three categories of GLP-1 analogs, are being developed and/or are in clinical use: short-acting, long-acting, and prolonged-acting GLP-1 analogs
Beyond Potency: The Safety Hazards of Visible Abnormalities The presence of visible particles is particularly concerning because this may: Represent peptide aggregation Microbial contamination Interaction between the drug and container components Even small particles that settle at the bottom of the vial warrant discarding the medication
No differences were observed in IBD-related hospitalizations or endoscopic scores
There are reports of beneficial changes in the gut microbiota by biguanides, but few other anti-diabetic drugs are reported 6,7,8
Semaglutide has been shown to be effective for weight loss in people with obesity